PRKAA1 and Insulin resistance: AMPK is considered a major target for drugs to combat the growing epidemic of metabolic disorders (Hardie et al., 2012) because AMPK activation elicits metabolic responses expected to counteract the physiological or metabolic abnormalities associated with obesity, insulin resistance, and type 2 diabetes.